The Trump Administration has taken a significant step toward loosening federal limits on medical marijuana, with the Justice Department announcing plans to reclassify certain cannabis products and broaden research opportunities. Acting Attorney General Todd Blanche confirmed he signed an order to shift FDA-approved and state-licensed medical marijuana from the strictest drug category, Schedule I, to Schedule III. This change places cannabis alongside substances recognized for medical use and with a lower risk of dependence. Schedule I drugs—such as heroin and LSD—are considered highly dangerous with no accepted medical value, while Schedule III drugs are defined as having “a moderate to...